Actelion announces definitive agreement to acquire US-based CoTherix, Inc.
The transaction has been approved unanimously by the Boards of Directors of both companies. Actelion will commence a cash tender offer of USD 13.50 per CoTherix Inc. share, for a total acquisition price of approximately USD 420 million (CHF 525 million). Subject to regulatory clearance and other customary closing conditions, the transaction is expected to conclude early in Q1 2007.
The directors and executive officers of CoTherix and additional stockholders, together owning approximately 32% of the outstanding shares, have agreed with Actelion to tender their shares pursuant to the offer, subject to customary terms and conditions, including termination rights.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.